Thomas E. Hughes
CIK 1611048 · See Remarks · last filed 2020-05-22
Thomas E. Hughes is a corporate insider who has filed 22 SEC Form 4 insider transactions across 2 companies since 2015. The most recent filing, for MGEN, was dated May 22, 2020. Across all open-market trades the lifetime net is −$2.3M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ZFGN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
ONE BROADWAY, 8TH FLOOR
CAMBRIDGE, MA 02142
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Director | 855 | — | — | -$48.3K | 9 | 2020-05-22 |
| Larimar Therapeutics, Inc. (ZFGN) Delisted | See Remarks | 10,437 | — | — | -$2.27M | 13 | 2018-06-29 |
Recent Filings
22 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-05-22 | Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-21 | Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-04-05 | Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-10-12 | Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Buy (P) | +10,000 | $47.7K | EDGAR |
| 2018-06-29 | Larimar Therapeutics, Inc. (ZFGN) Delisted | Sell (S) | −32,000 | -$320.0K | EDGAR |
| 2018-06-28 | Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-03-09 | Larimar Therapeutics, Inc. (ZFGN) Delisted | Sell (S) | −5,000 | -$50.0K | EDGAR |
| 2018-02-23 | Larimar Therapeutics, Inc. (ZFGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-01-05 | Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-12-22 | Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Sell (S) | −12,000 | -$96.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.